Authors: | Cheung, I. Y.; Feng, Y.; Cheung, N. K. V. |
Article Title: | Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma |
Abstract: | Molecular detection of minimal residual disease (MRD) measured by quantitative reverse transcription-polymerase chain reaction using a four-marker panel in the bone marrow (BM) after only two treatment cycles of anti-GD2 immunotherapy was a strong independent outcome predictor among high-risk patients with stage 4 neuroblastoma in first remission. While 32 of 46 MRD-negative patients relapsed within 2 years from immunotherapy, only four had marrow relapse; in three of these four patients, MRD turned positive in the subsequent BM. We conclude that negative MRD in the post-cycle two BM was rarely associated with BM relapse, but it did not exclude recurrences at other sites. Pediatr Blood Cancer 2013; 60: E32-E34. © 2013 Wiley Periodicals, Inc. |
Keywords: | cancer survival; controlled study; unclassified drug; major clinical study; cancer staging; cancer immunotherapy; reverse transcription polymerase chain reaction; granulocyte macrophage colony stimulating factor; relapse; high risk patient; monoclonal antibody; immunotherapy; neuroblastoma; minimal residual disease; isotretinoin; bone marrow disease; late relapse; marrow mrd; pfs; monoclonal antibody gd2 |
Journal Title: | Pediatric Blood and Cancer |
Volume: | 60 |
Issue: | 7 |
ISSN: | 1545-5009 |
Publisher: | Wiley Periodicals, Inc |
Date Published: | 2013-07-01 |
Start Page: | E32 |
End Page: | E34 |
Language: | English |
DOI: | 10.1002/pbc.24469 |
PROVIDER: | scopus |
PUBMED: | 23335404 |
DOI/URL: | |
Notes: | --- - "Export Date: 1 July 2013" - "CODEN: PBCEA" - "Source: Scopus" |